Neurodon Corp., a leader in the development of therapeutics targeting calcium homeostasis, is proud to announce that its CEO, Russell Dahl, Ph.D., will present at the 20th FASEB Conference on Calcium and Cell Function held in Winnipeg, Canada on July 6 – 10, 2025. Since 1987, this conference has been the eminent platform to present the latest breakthroughs in calcium signaling and related research. With presentations from some of the most highly cited academic researchers in the field, Neurodon is one of only 3 companies invited to present. The agenda includes a wide range of topics relating to molecular and cellular mechanisms of calcium signaling and homeostasis and the physiological and pathological effects in health and disease.
“This invitation to deliver a talk at FASEB Calcium is further validation that the field recognizes the potential of calcium pathways for drug development and Neurodon’s leadership in the area,” stated Dr. Dahl. “This year’s conference represents an exciting program that includes the latest research breakthroughs, technologies, and applications in the calcium field. I am looking forward to fruitful discussions with fellow researchers and experts about the subtleties of inter-organelle calcium signaling and disease relevance.”
In addition to presenting an overview of the Company’s innovative techniques that have enabled discovery and development of its first-in-class drug candidates, the company’s leading product, NRDN-101, has shown promising pre-clinical results in reversing pathology in models of diabetes and other metabolic conditions.
More information can be found here.
